



Abstract no.: MP. 1-9

Embracing the new normal in BPH surgery post COVID-19

Marius Chan, KH Siu, SY Yeung, CYC Chan, H Chow, ACY Ng, CM Ng, TY Chu, TYC Lam
Division of Urology, Department of Surgery
Princess Margaret Hospital, Hong Kong


Objective: To assess the acceptance and underlying reason of changing treatment modality in benign prostatic hyperplasia (BPH) surgery after COVID-19 pandemic

Patient and Methods: Patients with scheduled TURP from 1/2022 who were subsequently offered REZUM or Urolift under local anaesthesia were analysed.

Total patient	52
Age	Range: 57-97 Average: 73
Indication	Refractory retention: 17 Obstructive uropathy: 5 Recurrent AROU/ UTI: 7 Large residual urine: 1 Symptomatic: 22
Prostate size (cc)	Range: 33-80 Average: 53
On foley	23



Acceptance of changing treatment modality



Reasons of changing:

- Shorter waiting time 47%
- Lower surgical or anesthetic risk 26.5%
- Preservation of sexual function 26.5%

Reasons of not changing:

- Better surgical outcome 33%
- Worry about pain 33%
- Worry about prolong post-op urethral catheterization 33%

Conclusion: High acceptance rate in changing BPH surgery modality into REZUM or Urolift under local anaesthesia was shown. It may become a new normal after COVID-19 pandemic.